Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q3 2025 Earnings Call Transcript November 5, 2025
Recursion Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.36, expectations were $-0.38.
Christopher Gibson: “
Najat Khan: “
Ben Taylor: “
Christopher Gibson: Hello, everybody, and welcome to Recursion’s Third Quarter 2025 (L)earnings Call. My name is Chris Gibson. I’m the Co-Founder and current CEO of Recursion, and I’m so delighted to have you all joining us today. I want...
